Nektar Therapeutics (NKTR) presented data at the American Association for Cancer Research 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior antitumor activity, as well as greater and sustained exposure in plasma and tumor tissue, over docetaxel in preclinical models.
In a comparative study of NKTR-105 and docetaxel, NKTR-105 treatment significantly delayed tumor growth as compared to docetaxel , which was associated with greater and sustained tumor exposure to docetaxel after NKTR-105 administration.
In previous preclinical studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained therapeutic levels of docetaxel without the myelosuppression that is a dose-limiting toxicity for this widely-used cancer therapy.
NKTR-105 is currently being evaluated in a Phase 1 clinical trial in cancer patients. In the current trial of NKTR-105, the compound has required no pre-treatment with corticosteroids and shown no evidence of neutropenia in patients to date.
For comments and feedback: editorial@rttnews.com